Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Letrozole 9 Fluorodeoxyglucose F18 7 pembrolizumab 6 Magnetic Resonance Spectroscopy 6 atezolizumab 5 Blood Specimen Collection 5 Trastuzumab 4 Oncolytic Virotherapy 4 Biopsy 4 Bevacizumab 4 palbociclib 3 durvalumab 3 Vitamin D 3 Taxes 3 Saline Solution 3 Radiotherapy 3 Metformin 3 Fish Oils 3 Docosahexaenoic Acids 3 Denosumab 3 Carboplatin 3 Albumin-Bound Paclitaxel 3 pertuzumab 2 olaparib 2 bazedoxifene 2 Vinorelbine 2 Tamoxifen 2 Sentinel Lymph Node Biopsy 2 Positron-Emission Tomography 2 Positron Emission Tomography Computed Tomography 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × glembatumumab vedotin × Breast × Clear all

NCT03473691 2024-12-09

Breast50

University of Virginia

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡